SAR405 R ENANTIOMER NO FURTHER A MYSTERY

are large when compared with recent cefepime breakpoints, higher breakpoints of cefepime/zidebactam can be warranted for Acinetobacterisolates from all continents, whereas the susceptibility costs with the comparator agents have been normally lessen in Europe than the other geographic areas (Table 4).While in the APEKS-NP demo, which assessed all-b